Head-To-Head Comparison: AirSculpt Technologies (NASDAQ:AIRS) vs. InfuSystem (NYSE:INFU)
by Sarita Garza · The Markets DailyAirSculpt Technologies (NASDAQ:AIRS – Get Free Report) and InfuSystem (NYSE:INFU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Volatility & Risk
AirSculpt Technologies has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Valuation & Earnings
This table compares AirSculpt Technologies and InfuSystem”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AirSculpt Technologies | $151.82 million | 1.09 | -$11.67 million | ($0.18) | -12.78 |
| InfuSystem | $143.34 million | 1.76 | $870,000.00 | $0.41 | 30.44 |
InfuSystem has lower revenue, but higher earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AirSculpt Technologies and InfuSystem’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AirSculpt Technologies | -7.79% | -5.83% | -2.88% |
| InfuSystem | 1.12% | 2.78% | 1.41% |
Institutional & Insider Ownership
91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for AirSculpt Technologies and InfuSystem, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AirSculpt Technologies | 1 | 1 | 0 | 0 | 1.50 |
| InfuSystem | 0 | 1 | 3 | 0 | 2.75 |
AirSculpt Technologies currently has a consensus price target of $4.50, suggesting a potential upside of 95.65%. InfuSystem has a consensus price target of $16.67, suggesting a potential upside of 33.55%. Given AirSculpt Technologies’ higher probable upside, research analysts clearly believe AirSculpt Technologies is more favorable than InfuSystem.
Summary
InfuSystem beats AirSculpt Technologies on 9 of the 14 factors compared between the two stocks.
About AirSculpt Technologies
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
About InfuSystem
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.